Aurinia Pharma's takeout hopes dim with new legal challenge to key drug patent – STAT

Biotech & Pharma
Health Tech
Politics
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Adam Feuerstein March 2, 2022
Takeover speculation has swirled around Aurinia Pharmaceuticals since late 2019 when its lead drug, Lupkynis, proved to be an effective treatment for lupus nephritis in a pivotal Phase 3 clinical trial. After Aurinia secured Lupkynis’ U.S. approval in January 2021, shareholders practically demanded its management team put the company up for sale, rather than try to sell the drug on its own.
But despite more than a few rumors and false alarms, Aurinia remains un-bought. This week, a problematic impediment to the company’s sale surfaced: Lupkynis’ patent life might not be as strong or long as it had hoped.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Senior Writer, Biotech
Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast.



This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Adam Feuerstein
By Nicholas Florko
advertisement
By Megan Molteni
By Adam Feuerstein
By Casey Ross
Reporting from the frontiers of health and medicine

source

Add a Comment

Your email address will not be published. Required fields are marked *